Serum melatonin levels may predict mortality in patients with traumatic brain injury

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-03-15 03:30 GMT   |   Update On 2022-03-15 03:30 GMT

Spain: A new study conducted by Leonardo Lorente and the team showed the existence of greater blood melatonin levels in non-survivors than in survivors on days 1, 4, and 8 following traumatic brain injury (TBI), as well as the capability to predict 30-day mortality for serum melatonin levels evaluated at these time points. The findings of this study were published in the journal...

Login or Register to read the full article

Spain: A new study conducted by Leonardo Lorente and the team showed the existence of greater blood melatonin levels in non-survivors than in survivors on days 1, 4, and 8 following traumatic brain injury (TBI), as well as the capability to predict 30-day mortality for serum melatonin levels evaluated at these time points. The findings of this study were published in the journal Anaesthesia Critical Care & Pain Medicine.

Secondary brain damage may occur following TBI as a result of neuroinflammation, oxidation, and apoptosis. On admission for TBI, non-surviving patients had higher levels of serum melatonin than surviving patients. Thus, the goal of this study was to determine serum melatonin levels in the 1st week of TBI in surviving and non-surviving patients, as well as to determine if serum melatonin levels during the first week of TBI may be used to predict mortality.

For this study, patients with an isolated and severe TBI were included if they received 10 points on the non-cranial elements of the Injury Severity Score and 9 points on the Glasgow Coma Scale. Serum melatonin levels were assessed on days 1, 4, and 8 after TBI. The study's endpoint was 30-day mortality.

The results of this study stated as follow:

1. On days 1, 4, and 8 following TBI, surviving patients (n = 90) had lower blood melatonin levels than non-survivors (n = 34).

2. The area under the curve for the prediction of 30-day mortality on days 1, 4, and 8 after TBI was 0.85, 0.82, and 0.71 respectively.

In conclusion, the existence of greater levels of serum melatonin on days 1, 4, and 8 following TBI in non-survivors than in survivors, as well as the ability to predict 30-day mortality for serum melatonin levels tested at these time points, were the study's novel results. More study, however, is required to corroborate our findings.

Reference:

Lorente L, Martín MM, Ruiz C, Abreu-González P, Ramos-Gómez L, Argueso M, Sole-Violan J, Cáceres JJ, Jiménez A. Serum melatonin levels in predicting mortality in patients with severe traumatic brain injury. Anaesth Crit Care Pain Med. 2021 Dec;40(6):100966. doi:10.1016/j.accpm.2021.100966. Epub 2021 Oct 27. PMID: 34718184.

Tags:    
Article Source : Anaesthesia Critical Care & Pain Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News